Tirzepatide Reconstitution Calculator

Yes. Approved as Mounjaro for type 2 diabetes (May 2022) and as Zepbound for chronic weight management (Nov 2023) in adults with BMI ≥30 kg/m², or ≥27 kg/m² plus ≥1 weight-related comorbidity. Zepbound also holds the first approval for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity (Dec 2024).

Pooled meta-analysis: mean 9.36% body-weight reduction across GLP-1RAs/dual agonists; treatment ≥72 weeks and dual GIP/GLP-1 agonism yield greater loss. (meta-analysis) Real-world UK cohort (n=630,545): −13.5% at 6 months, −17.4% at 12 months; 89.9% achieve ≥5% and 72.1% ≥10% by month 6, frequently on intermediate doses. (observational) Response is typically smaller with comorbid T2D, OSA, or MAFLD.

Start 2.5 mg subcutaneously once weekly, then escalate in 2.5 mg steps at ≥4-week intervals (5 → 7.5 → 10 → 12.5 → 15 mg), pausing at the lowest effective dose (practitioner consensus). Low-dose maintenance is evidence-supported: 2.5 vs 5 mg produced similar 6-month weight loss in Japanese adults (−15.3% vs −16.1%) with fewer adverse events on 2.5 mg (35% vs 50%). (observational) Real-world titration is faster than with semaglutide (median 32 vs 143 days; 77.6% vs 52.9% reach max dose). (observational) Most adverse events cluster within the first 30 days, escalate conservatively. (pharmacovigilance)

Head-to-head meta-analysis (41,381 participants): tirzepatide beat semaglutide by 4.28 percentage points of weight loss (−4.43 kg) and 0.29% greater HbA1c reduction, with higher odds of ≥10/15/20% loss but no difference at ≥5%. (meta-analysis) Serious adverse events were more frequent with tirzepatide (RR 1.83); discontinuations were similar. Dose, not drug identity, drives much of the difference: semaglutide 2.4 mg ≈ tirzepatide 10 mg (99.4% equivalence probability); semaglutide 7.2 mg ≈ tirzepatide 15 mg (94.8%). (model-based analysis)

GI effects dominate (nausea, diarrhea, vomiting, decreased appetite), with median onset at 13 days; 67.1% occur within 30 days. (pharmacovigilance) Severe motility events, constipation, gastroparesis, obstruction, occur in roughly 1 per 100 person-years, 37% higher than with SGLT2 inhibitors. (observational) Starvation ketoacidosis is a strong pharmacovigilance signal (PRR 70.2): consider ketone testing when nausea accompanies heavy caloric restriction. (pharmacovigilance) Hair loss is reported with tirzepatide; likely rapid-weight-loss telogen effluvium, causality unproven. (review)

Discontinue before planned conception. Animal data show teratogenicity, but human cohorts of early accidental exposure report no increased malformation signal to date. (review) Delayed gastric emptying can reduce oral contraceptive absorption, use backup contraception for 4 weeks after initiation and after every dose escalation (practitioner consensus). Planned discontinuation well before pregnancy did not raise gestational diabetes (GDM) risk; abrupt discontinuation ≤90 days before conception raised GDM risk 53% (RR 1.536). (observational)

Treat it as chronic therapy. Under Japan's mandated 72-week treatment cap, 95% of patients regained weight within 2 months of forced cessation and 83% by 6 months. (observational) Treatment continuity predicts greater weight loss. Regain after stopping is the expected outcome without ongoing metabolic and lifestyle support.

Branded and compounded tirzepatide showed statistically equivalent 6-month weight loss (11.4% vs 11.4%) in a propensity-matched telehealth cohort (718 pairs) within a ±2 percentage-point pre-specified margin. (observational) Value depends on your pharmacy tier: compounded saves ~$6,000/6 months vs retail cash price and ~$1,494 vs LillyDirect maintenance dosing, but costs more than branded when insurance copays run below ~$200/month. Verify which price tier applies to you before assuming compounded is cheaper.